BioHarvest Sciences (NASDAQ:BHST – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04), FiscalAI reports. The company had revenue of $8.84 million for the quarter, compared to analyst estimates of $9.45 million. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%.
BioHarvest Sciences Price Performance
Shares of BHST traded up $0.11 during mid-day trading on Wednesday, reaching $2.19. 9,393 shares of the company’s stock were exchanged, compared to its average volume of 36,693. The company has a quick ratio of 2.44, a current ratio of 2.96 and a debt-to-equity ratio of 0.03. BioHarvest Sciences has a 52-week low of $1.82 and a 52-week high of $12.80. The company has a market cap of $42.99 million, a price-to-earnings ratio of -3.71 and a beta of 0.97. The company has a 50-day simple moving average of $2.74 and a two-hundred day simple moving average of $3.80.
Analyst Upgrades and Downgrades
BHST has been the topic of several research reports. Maxim Group set a $5.00 target price on BioHarvest Sciences in a report on Wednesday. Weiss Ratings raised BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $7.50.
Institutional Investors Weigh In On BioHarvest Sciences
A number of large investors have recently bought and sold shares of BHST. Virtu Financial LLC purchased a new stake in BioHarvest Sciences in the 4th quarter valued at about $60,000. Geode Capital Management LLC purchased a new position in shares of BioHarvest Sciences during the 4th quarter worth about $61,000. HRT Financial LP purchased a new position in shares of BioHarvest Sciences during the 4th quarter worth about $75,000. Marshall Wace LLP acquired a new stake in shares of BioHarvest Sciences in the fourth quarter worth approximately $110,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of BioHarvest Sciences in the fourth quarter worth approximately $140,000.
Trending Headlines about BioHarvest Sciences
Here are the key news stories impacting BioHarvest Sciences this week:
- Positive Sentiment: BioHarvest secured an exclusive manufacturing and supply agreement for a rare botanical fragrance compound, covering a planned 20-ton production program through 2027 and 2028. The agreement is estimated to generate approximately $20 million to $30 million in revenue and could support a more profitable, higher-margin contract development and manufacturing (CDMO) business. BioHarvest Secures 20-Ton Manufacturing and Supply Agreement
- Positive Sentiment: Second-quarter revenue rose 3.8% year over year to approximately $8.8 million. Management said spending is being redirected toward manufacturing capacity, with the fragrance contract providing a foundation for future collaborations in sustainable luxury fragrance production. BioHarvest posts higher Q2 revenue and secures manufacturing deal
- Neutral Sentiment: The company filed its second-quarter 2026 interim financial statements and management discussion and analysis, while earnings-call materials provided additional detail on the results and business update. BioHarvest Sciences Files Q2 2026 Interim Financials and MD&A
- Neutral Sentiment: Reported short interest was listed at zero shares, implying no measurable short-interest overhang based on the supplied data. BioHarvest Sciences Nasdaq Composite Focus
- Negative Sentiment: BioHarvest reported a second-quarter loss of $0.17 per share, wider than the expected $0.13 loss and the $0.15 loss recorded a year earlier. Revenue of $8.84 million also missed the $9.45 million consensus estimate, while profitability remained weak. BioHarvest Sciences Reports Q2 Loss and Lags Revenue Estimates
- Negative Sentiment: Fiscal 2026 revenue guidance of $37 million to $40 million is below the analyst consensus estimate of $42.9 million, signaling near-term pressure on sales expectations. BioHarvest Reports Second Quarter 2026 Financial Results
BioHarvest Sciences Company Profile
BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.
The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.
Read More
- Five stocks we like better than BioHarvest Sciences
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
- TSMC’s 44.7% Sales Surge Signals the AI Boom Is Still Alive
- CoreWeave’s $129 Billion AI Backlog Changes the Bull Case
- Tesla’s Robotaxi Reality Check: Time to Deliver
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
